Skip to Main Content

Author Details

Chien-Te K Tseng
The University of Texas Medical Branch
1991
91
48
PMIDPaper TitleJournal TitlePublished Year
36969239A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.Front Immunol2023
37441066Circulating Reelin promotes inflammation and modulates disease activity in acute and long COVID-19 cases.Front Immunol2023
34730959Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L.J Med Chem2022
35665009The DNA glycosylase NEIL2 plays a vital role in combating SARS-CoV-2 infection.Res Sq2022
35860632Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents.Front Chem2022
36469521Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines.PLoS One2022
36001674Comparison of replicating and nonreplicating vaccines against SARS-CoV-2.Sci Adv2022
35900097A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.mBio2022
35982307Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.Nat Med2022
35313595Parsing the role of NSP1 in SARS-CoV-2 infection.bioRxiv2022
35086724Efficacy and self-similarity of SARS-CoV-2 thermal decontamination.J Hazard Mater2022
35169121Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD.Cell Discov2022
33283984A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.ChemMedChem2021
33597253Bepridil is potent against SARS-CoV-2 in vitro.Proc Natl Acad Sci U S A2021
33787221A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.ACS Chem Biol2021
33501450A Universal Bacteriophage T4 Nanoparticle Platform to Design Multiplex SARS-CoV-2 Vaccine Candidates by CRISPR Engineering.bioRxiv2021
35062273Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.Viruses2021
34492082Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.PLoS Pathog2021
34516878A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering.Sci Adv2021
34161386The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.PLoS One2021
34155200Author Correction: A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.Nat Commun2021
34288674Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.J Med Chem2021
32511385Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune Enhancement.bioRxiv2020
31883090Quantification of the Middle East Respiratory Syndrome-Coronavirus RNA in Tissues by Quantitative Real-Time RT-PCR.Methods Mol Biol2020
33060595A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.Nat Commun2020
33310780Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection <i>In Vitro</i>.mBio2020
33140046A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.bioRxiv2020
33139569Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.Proc Natl Acad Sci U S A2020
33398273Potent <i>in vitro</i> anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L.bioRxiv2020
33236012The Development of a Novel Nanobody Therapeutic for SARS-CoV-2.bioRxiv2020
33039209Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.Vaccine2020
32607511A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.bioRxiv2020
32941803High Potency of a Bivalent Human V<sub>H</sub> Domain in SARS-CoV-2 Animal Models.Cell2020
32766582A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors.bioRxiv2020
32706609Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice.Am J Respir Cell Mol Biol2020
32759966A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.Cell Res2020
33010978Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.Vaccine2020
32544372Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.MAbs2020
30911758A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model.J Infect Dis2019
32313544Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.Adv Funct Mater2019
30256968Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease.J Infect Dis2019
30989115A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.Sci Adv2019
29496347Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.Vaccine2018
28277821Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.Hum Vaccin Immunother2017
25640653Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.Cell Mol Immunol2016
27874853Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Nat Commun2016
27750111A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.Virology2016
27538452Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection.Sci Rep2016
27269431Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.Hum Vaccin Immunother2016
25589660Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease.J Virol2015
  • 1 - 50 of 91

Recommended Authors

Tianyang Mao
Yale University School of Medicine
Career Start Year 2017
Number of shared co-authors 0
James Logue
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 2017
Number of shared co-authors 3
Raveen Rathnasinghe
Icahn School of Medicine at Mount Sinai New York
Career Start Year 2015
Number of shared co-authors 1
Stuart Weston
University of Maryland School of Medicine
Career Start Year 2014
Number of shared co-authors 3
Erik Van Dis
University of California berkeley
Career Start Year 2014
Number of shared co-authors 3
Peiwen Lu
Yale University School of Medicine
Career Start Year 2013
Number of shared co-authors 0
Chengjin Ye
Texas Biomedical Research Institute
Career Start Year 2013
Number of shared co-authors 0
R??my Robinot
Institut Pasteur, Universite Paris Cite, CNRS UMR 9
Career Start Year 2012
Number of shared co-authors 0
Mary K McCarthy
University of Colorado School of Medicine
Career Start Year 2012
Number of shared co-authors 8
Shashank Tripathi
Indian Institute of Science
Career Start Year 2011
Number of shared co-authors 1
Benjamin Israelow
Yale University School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Craig B Wilen
Yale School of Medicine
Career Start Year 2010
Number of shared co-authors 3
Siyuan Ding
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 0
Hans-Heinrich Hoffmann
The Rockefeller University
Career Start Year 2008
Number of shared co-authors 3
Michael Schotsaert
Icahn School of Medicine at Mount Sinai
Career Start Year 2008
Number of shared co-authors 2
Melissa M Coughlin
Centers for Disease Control and Prevention
Career Start Year 2006
Number of shared co-authors 0
Sudhakar Agnihothram
National Center for Toxicological Research
Career Start Year 2005
Number of shared co-authors 23
Emmie de Wit
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 2004
Number of shared co-authors 4
Natalie J Thornburg
Centers for Disease Control and Prevention (CDC)
Career Start Year 2003
Number of shared co-authors 8
Luis Martinez-Sobrido
Texas Biomedical Research Institute
Career Start Year 2001
Number of shared co-authors 3
Thomas E Morrison
University of Colorado Anschutz Medical Campus
Career Start Year 2001
Number of shared co-authors 9
Gary P Kobinger
University of Texas Medical Branch
Career Start Year 1997
Number of shared co-authors 4
Larissa B Thackray
Washington University School of Medicine
Career Start Year 1996
Number of shared co-authors 14
Shelly J Robertson
National Institute of Allergy and Infectious Diseases
Career Start Year 1995
Number of shared co-authors 5
Boyd L Yount
University of North Carolina at Chapel Hill
Career Start Year 1993
Number of shared co-authors 24
Matthew B Frieman
Center for Pathogen Research, University of Maryland School of Medicine
Career Start Year 1993
Number of shared co-authors 12
Lucy Thorne
University College London
Career Start Year 1992
Number of shared co-authors 0
Akiko Iwasaki
Yale University
Career Start Year 1990
Number of shared co-authors 1
Bart L Haagmans
Erasmus Medical Center
Career Start Year 1986
Number of shared co-authors 6
Michael S Diamond
Washington University School of Medicine
Career Start Year 1982
Number of shared co-authors 18

Collaborators

Clarence J Peters
University of Texas Medical Branch at Galveston
Co-authored papers 14
Dimiter S Dimitrov
Co-authored papers 6
Ralph S Baric
University of North Carolina
Co-authored papers 5
Laura Beretta
Co-authored papers 4
James H McKerrow
Sandler Center for Drug Discovery, University of California San Francisco
Co-authored papers 4
Vineet D Menachery
University of Texas Medical Branch
Co-authored papers 4
Anthony J O'Donoghue
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Co-authored papers 4
Slobodan Paessler
Co-authored papers 3
Pei-Yong Shi
University of Texas Medical Branch
Co-authored papers 3
Xuping Xie
University of Texas Medical Branch
Co-authored papers 3
Alexandra Sch??fer
University of North Carolina at Chapel Hill
Co-authored papers 3
Sarah R Leist
University of North Carolina at Chapel Hill
Co-authored papers 3
Vivian Hook
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Co-authored papers 3
Pingwei Li
Texas A&M University, College Station
Co-authored papers 2
Aaron F Carlin
Co-authored papers 2
Frank M Raushel
Texas A&M University, College Station
Co-authored papers 2
Lisa E Gralinski
University of North Carolina at Chapel Hill
Co-authored papers 2
Mark Larance
The University of Sydney
Co-authored papers 2
William H Gerwick
Scripps Institution of Oceanography, University of California San Diego
Co-authored papers 2
Bobbie-Jo M Webb-Robertson
Pacific Northwest National Laboratory
Co-authored papers 1
Noah Stern
Weizmann Institute of Science
Co-authored papers 1
Amy C Sims
The University of North Carolina at Chapel Hill
Co-authored papers 1
Hua Jiang
Co-authored papers 1
Michael G Katze
University of Washington
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Khanh Nguyen
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen
Co-authored papers 1
Rhiju Das
Stanford University School of Medicine
Co-authored papers 1
Casey Long
University of North Carolina at Chapel Hill
Co-authored papers 1
Qiaobing Xu
Co-authored papers 1
Armand Bankhead
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 1
Release 1.2